Parvus Therapeutics and Genentech have forged a global collaboration and license agreement to develop, manufacture and commercialise novel Navacim therapeutics for treating inflammatory bowel disease, autoimmune liver diseases and celiac disease.
Parvus will receive an undisclosed upfront payment and is eligible to receive research, development and commercialisation milestone payments for each disease area within the collaboration, based on achievement of certain predetermined milestones.
Parvus is also eligible to receive certain additional milestone payments in other disease areas, as well as royalties on net sales of products resulting from the collaboration.
“Our collaboration with Genentech is now the second partnership that we’ve entered into with a major biopharmaceutical company, which we believe reinforces the potential of our Navacim immunoregulatory therapeutic platform,” said Curtis Ruegg, President & CEO of Parvus.
“Partnering with Genentech will enable Parvus to expand the Navacim pipeline to address several debilitating autoimmune diseases in gastroenterology.”
Under the terms of the Agreement, Parvus will conduct pre-clinical development and clinical development activities through Phase I.
Genentech will be responsible for clinical development from Phase II and beyond, including global regulatory submissions and worldwide commercialisation of products.